Universidad de Alcalá

COMPOUNDS FOR THE TREATMENT OF LEISHMANIA INFECTIONS

Patent
ES2526935 B2

Code

BIO_UAH_30

Application areas

- Biological Sciences, Health and Pharma

Type of Collaboration

- Technical cooperation
- License agreement
- Commercial agreement with technical assistance

Main Researchers

Prof. Antonio Jiménez Ruiz

CONTACT

OTRI Universidad de Alcalá
Escuela Politécnica Superior
Campus Científico-Tecnológico
28805, Alcalá de Henares
(Madrid)
(+34) 91 885 45 61
otriuah@uah.es

@otriuah

OTRI Universidad de Alcalá



I

Estructura de nuevos compuestos de Fórmula I

ABSTRACT

Preparation and uses of a series of compounds that act as bioactive agents against the Leishmania parasite and as therapeutic agents in the treatment of this disease, in both, its visceral (LV) version and in the mucocutaneous one (CML).
The preparation and use of the structures of pyridazino [1 ', 6': 1,2] pyrido [3,4-b] indolinium salts presented can be an interesting solution for the treatment of the disease, the infections caused by the parasite and to inhibit the growth of this one.
The present invention relates to a pharmaceutical composition comprising at least one of the compounds of the invention, together with a pharmaceutically acceptable vehicle.
The pharmaceutically acceptable adjuvants and vehicles that can be used in said compositions are the adjuvants and vehicles known to those skilled in the art and commonly used in the preparation of therapeutic compositions.

ADVANTAGES AND INNOVATIONS

- The compounds of the invention produce less toxicity and fewer side effects in the patient.
- The compounds of the invention are pharmaceutically acceptable salts, prodrugs and/or solvates, as well as pharmaceutical compositions containing them. They can be used together with other drugs, or additional active ingredients, to provide a combination therapy.
- This new result has good specificity for the Leishmania parasite and would be a competitive advantage for that pharmaceutical company that would manufacture an active ingredient for the formulation of a leishmanicidal drug.
- Given the similarity of the different species of Leishmania, the compounds of the invention are used for the treatment of any type of leishmaniasis. Both visceral (LV) and mucocutaneous (LMC).
- The therapeutic composition can be prepared in solid form or aqueous suspension, in a pharmaceutically acceptable diluent.
- It can be administered by any appropriate route of administration: oral, topical, rectal or parenteral.